Biomarkers for rheumatoid arthritis: From molecular processes to diagnostic applications-current concepts and future perspectives

Britt Nakken, Gábor Papp, Vidar Bosnes, M. Zeher, György Nagy, Peter Szodoray

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Early diagnosis and immediately started appropriate treatment are mandatory for the prevention of radiographic progression, functional disability and unfavourable disease outcome in rheumatoid arthritis (RA). The current classification criteria for RA include two different types of biomarkers representing inflammatory processes, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) or immune processes including autoantibodies, such as rheumatoid factor (RF) and antibodies against citrullinated proteins (ACPA). After the discovery of RF, the recent recognition of various autoantibodies against post-translationally modified proteins opened new avenues to diagnosing RA and predicting the course of the disease. Citrullination and carbamylation of amino acids generate new epitopes that can potentially promote the production of novel autoantibodies. In spite of growing knowledge, the pathogenic role of these autoantibodies is still not fully elucidated in RA. In this paper, we review the currently available and novel promising immune biomarkers, which may help in early diagnosis and estimating prognosis in RA.

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalImmunology Letters
Volume189
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Rheumatoid Arthritis
Biomarkers
Autoantibodies
Rheumatoid Factor
Early Diagnosis
Blood Sedimentation
C-Reactive Protein
Epitopes
Proteins
Amino Acids
Antibodies

Keywords

  • Autoimmunity
  • Citrullination
  • Diagnosis and prognosis
  • Rheumatoid arthritis
  • Rheumatoid factor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Biomarkers for rheumatoid arthritis : From molecular processes to diagnostic applications-current concepts and future perspectives. / Nakken, Britt; Papp, Gábor; Bosnes, Vidar; Zeher, M.; Nagy, György; Szodoray, Peter.

In: Immunology Letters, Vol. 189, 01.09.2017, p. 13-18.

Research output: Contribution to journalReview article

Nakken, Britt ; Papp, Gábor ; Bosnes, Vidar ; Zeher, M. ; Nagy, György ; Szodoray, Peter. / Biomarkers for rheumatoid arthritis : From molecular processes to diagnostic applications-current concepts and future perspectives. In: Immunology Letters. 2017 ; Vol. 189. pp. 13-18.
@article{ddb702e7ba53492a8900f0eecd13fcd2,
title = "Biomarkers for rheumatoid arthritis: From molecular processes to diagnostic applications-current concepts and future perspectives",
abstract = "Early diagnosis and immediately started appropriate treatment are mandatory for the prevention of radiographic progression, functional disability and unfavourable disease outcome in rheumatoid arthritis (RA). The current classification criteria for RA include two different types of biomarkers representing inflammatory processes, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) or immune processes including autoantibodies, such as rheumatoid factor (RF) and antibodies against citrullinated proteins (ACPA). After the discovery of RF, the recent recognition of various autoantibodies against post-translationally modified proteins opened new avenues to diagnosing RA and predicting the course of the disease. Citrullination and carbamylation of amino acids generate new epitopes that can potentially promote the production of novel autoantibodies. In spite of growing knowledge, the pathogenic role of these autoantibodies is still not fully elucidated in RA. In this paper, we review the currently available and novel promising immune biomarkers, which may help in early diagnosis and estimating prognosis in RA.",
keywords = "Autoimmunity, Citrullination, Diagnosis and prognosis, Rheumatoid arthritis, Rheumatoid factor",
author = "Britt Nakken and G{\'a}bor Papp and Vidar Bosnes and M. Zeher and Gy{\"o}rgy Nagy and Peter Szodoray",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.imlet.2017.05.010",
language = "English",
volume = "189",
pages = "13--18",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",

}

TY - JOUR

T1 - Biomarkers for rheumatoid arthritis

T2 - From molecular processes to diagnostic applications-current concepts and future perspectives

AU - Nakken, Britt

AU - Papp, Gábor

AU - Bosnes, Vidar

AU - Zeher, M.

AU - Nagy, György

AU - Szodoray, Peter

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Early diagnosis and immediately started appropriate treatment are mandatory for the prevention of radiographic progression, functional disability and unfavourable disease outcome in rheumatoid arthritis (RA). The current classification criteria for RA include two different types of biomarkers representing inflammatory processes, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) or immune processes including autoantibodies, such as rheumatoid factor (RF) and antibodies against citrullinated proteins (ACPA). After the discovery of RF, the recent recognition of various autoantibodies against post-translationally modified proteins opened new avenues to diagnosing RA and predicting the course of the disease. Citrullination and carbamylation of amino acids generate new epitopes that can potentially promote the production of novel autoantibodies. In spite of growing knowledge, the pathogenic role of these autoantibodies is still not fully elucidated in RA. In this paper, we review the currently available and novel promising immune biomarkers, which may help in early diagnosis and estimating prognosis in RA.

AB - Early diagnosis and immediately started appropriate treatment are mandatory for the prevention of radiographic progression, functional disability and unfavourable disease outcome in rheumatoid arthritis (RA). The current classification criteria for RA include two different types of biomarkers representing inflammatory processes, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) or immune processes including autoantibodies, such as rheumatoid factor (RF) and antibodies against citrullinated proteins (ACPA). After the discovery of RF, the recent recognition of various autoantibodies against post-translationally modified proteins opened new avenues to diagnosing RA and predicting the course of the disease. Citrullination and carbamylation of amino acids generate new epitopes that can potentially promote the production of novel autoantibodies. In spite of growing knowledge, the pathogenic role of these autoantibodies is still not fully elucidated in RA. In this paper, we review the currently available and novel promising immune biomarkers, which may help in early diagnosis and estimating prognosis in RA.

KW - Autoimmunity

KW - Citrullination

KW - Diagnosis and prognosis

KW - Rheumatoid arthritis

KW - Rheumatoid factor

UR - http://www.scopus.com/inward/record.url?scp=85019561338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019561338&partnerID=8YFLogxK

U2 - 10.1016/j.imlet.2017.05.010

DO - 10.1016/j.imlet.2017.05.010

M3 - Review article

C2 - 28526580

AN - SCOPUS:85019561338

VL - 189

SP - 13

EP - 18

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

ER -